GlobeNewswire Inc | Sep 8, 2021 08:00AM EDT

September 08, 2021

BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (Caladrius or the Company), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CEO of Caladrius, will provide a corporate update and participate in one-on-one investor meetings at the H.C. Wainwright 23rdAnnual Global Investment Conference to be held September 13-15, 2021.

The presentation will be available on-demand through the H.C. Wainwrightconference portal, starting at 7:00 a.m. ET on Monday, September 13, 2021.

If you are an institutional investor and would like to listen to the Companys presentation, please click on the following link to register for the conference: https://hcwevents.com/annualconference/.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Companys current product candidates include: CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study (www.freedom-trial.com) in the U.S. for the treatment of coronary microvascular dysfunction (CMD); CLBS12 (HONEDRA in Japan), recipient of orphan designation for Buergers Disease in the U.S. and, in Japan, recipient of a SAKIGAKE designation and eligible for early conditional approval for the treatment of critical limb ischemia (CLI) and Buergers Disease based on the results of an ongoing clinical trial; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for diabetic kidney disease (DKD).For more information on the Company, please visitwww.caladrius.com.

Contact:

Investors:Caladrius Biosciences, Inc.John MendittoVice President, Investor Relations and Corporate CommunicationsPhone:908-842-0084Email:jmenditto@caladrius.com

Media: Real ChemistryRachel GirardReal ChemistryPhone: 401-477-4030Email: rgirard@realchemistry.com